In fact, standard MIS-C treatment already includes intravenous immunoglobulin (IVIG) and glucocorticoids, and in refractory cases, IL-1 blockade (anakinra) has been used, which is the same armamentarium used for HLH/MAS. Here, IL1B is linked to macrophage activation syndrome.